RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Alexion Pharmaceuticals Market capitalization 2024

Alexion Pharmaceuticals Market capitalization

40.52 B USD

Alexion Pharmaceuticals Dividend yield

Ticker

ALXN

ISIN

US0153511094

WKN

899527

In 2024, Alexion Pharmaceuticals's market cap stood at 40.52 B USD, a 75.48% increase from the 23.09 B USD market cap in the previous year.

The Alexion Pharmaceuticals Market capitalization history

YEARREVENUE (undefined USD)GROSS MARGIN (%)NET INCOME (undefined USD)
2025e8.8662,264.43
2024e8.1167,983.99
2023e7.6472,173.77
2022e7.2476,203.33
2021e6.6582,892.88
20206.0790,880.6
20194.9992,102.4
20184.1390,940.08
20173.5587,210.44
20163.0891,620.4
20152.691,050.14
20142.2392,220.66
20131.5589,150.25
20121.1388,870.25
20110.7888,120.18
20100.5488,080.1
20090.3988,340.3
20080.2689,040.03
20070.0790,69-0.09
20060100,00-0.13
20050100,00-0.06
20040119921,74-0.07
20030612933,33-0.08
20020.0184867,69-0.06
20010.0146749,15-0.06

Alexion Pharmaceuticals Aktienanalyse

What does Alexion Pharmaceuticals do?

Alexion Pharmaceuticals Inc. is a US biotechnology company specializing in the development and commercialization of drugs for the treatment of rare diseases. It was founded in 1992 and is headquartered in Boston, Massachusetts. The history of Alexion began with the discovery of the protein C5a, which is responsible for the occurrence of inflammation. Alexion then developed the first medication, Soliris, specifically for the treatment of the rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH). Soliris is classified as a monoclonal antibody and inhibits the protein C5a, which is responsible for inflammation. Alexion's business model focuses primarily on developing drugs for rare diseases. These diseases are unprofitable for most major pharmaceutical companies because they have a small patient base. However, Alexion has begun to identify and develop drugs for such diseases that are tailored to these specific patients. Such drugs are not suitable for the majority of the patient population as they are very expensive. Alexion is divided into several divisions focused on the development and launch of drugs for specific diseases. The most well-known division is PNH, but the company has also developed drugs for rare hematological, nephrological, neurological, immunological, and metabolic diseases. Alexion has also developed the ability to bring drugs to market faster than other pharmaceutical companies by employing innovative clinical trial methods. In addition to Soliris, Alexion has developed other drugs such as Ultomiris, Strensiq, and Kanuma. Ultomiris is a successor to Soliris and is used to treat PNH and aHUS. Strensiq is used for patients with hypophosphatasia, while Kanuma was developed for patients with lysosomal storage diseases such as children with Gaucher disease or Fabry disease. Alexion also collaborates with other companies to develop and market drugs for rare diseases. The most well-known example is the collaboration with the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation to develop the drug ALXN1210, which Alexion hopes will surpass both Soliris and Ultomiris. The collaboration has the potential to provide groundbreaking treatment for PNH, aHUS, and other rare diseases. Overall, in recent years, Alexion Pharmaceuticals Inc. has become an important player in the market for rare diseases. The company has taken on challenging tasks by striving to uncover rare diseases and gaps and then finding new, unique solutions to treat these diseases. In the future, Alexion will continue its efforts in researching and developing drugs for rare diseases and will continue to provide innovative solutions and therapeutic approaches to improve the lives of patients. Alexion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Alexion Pharmaceuticals revenue by segment

In the annual report of the Alexion Pharmaceuticals share (US0153511094, 899527, ALXN), it breaks down its revenues into 1 segments: 1. Therapies. The Alexion Pharmaceuticals stock (WKN: 899527, ISIN: US0153511094, Ticker Symbol: ALXN) is a leading investment for investors interested in participating in the Health Care sector.

Market capitalization Details

Exploring Alexion Pharmaceuticals's Market Capitalization

Alexion Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Alexion Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Alexion Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Alexion Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Alexion Pharmaceuticals Stock

What is the current Alexion Pharmaceuticals market capitalization?

The current market capitalization of Alexion Pharmaceuticals is 40.52 B USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Alexion Pharmaceuticals.

How has the market capitalization of Alexion Pharmaceuticals developed in recent years?

The market capitalization of Alexion Pharmaceuticals has increased/decreased by 75.48% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Alexion Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Alexion Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Alexion Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Alexion Pharmaceuticals pay?

Over the past 12 months, Alexion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alexion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Alexion Pharmaceuticals?

The current dividend yield of Alexion Pharmaceuticals is .

When does Alexion Pharmaceuticals pay dividends?

Alexion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alexion Pharmaceuticals?

Alexion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Alexion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alexion Pharmaceuticals located?

Alexion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alexion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alexion Pharmaceuticals from 4/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/19/2024.

When did Alexion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/19/2024.

What was the dividend of Alexion Pharmaceuticals in the year 2023?

In the year 2023, Alexion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Alexion Pharmaceuticals pay out the dividend?

The dividends of Alexion Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Alexion Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Alexion Pharmaceuticals

Our stock analysis for Alexion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alexion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.